Galectin Therapeutics (GALT) Change in Cash (2010 - 2026)

Galectin Therapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• In Q1 2026, Change in Cash rose 53.06% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at $6.7 million (up 141.43% YoY), while the FY2025 annual figure was $2.6 million, up 124.67% from the prior year.
• Change in Cash for Q1 2026 stood at -$3.6 million, down from $6.2 million in the prior quarter.
• The five-year high for Change in Cash was $6.3 million in Q2 2025, with the low at -$11.9 million in Q4 2024.
• The 5-year median for Change in Cash is -$793000.0 (2023), against an average of -$1.5 million.
• Peak annual rise in Change in Cash reached 1123.35% in 2024, while the deepest fall reached 325.37% in 2024.
• Galectin Therapeutics' Change in Cash stood at $2.8 million in 2022, then jumped by 91.89% to $5.3 million in 2023, then plunged by 325.37% to -$11.9 million in 2024, then soared by 151.88% to $6.2 million in 2025, then slumped by 158.26% to -$3.6 million in 2026.
• Business Quant data shows GALT's Change in Cash at -$3.6 million in Q1 2026, $6.2 million in Q4 2025, and -$2.2 million in Q3 2025.